Joseph Marvyn Neri, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 220 Burdette St, Saint Ignace, MI 49781 Phone: 906-643-8585 Fax: 906-643-9036 |
Mr. Matthew A Bowes, MD Emergency Medicine - Emergency Medical Services Medicare: Accepting Medicare Assignments Practice Location: 1140 N State St, Saint Ignace, MI 49781 Phone: 906-643-8585 |
Dr. Darrin J Benzing, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1140 N State St, Saint Ignace, MI 49781 Phone: 906-643-8585 |
Jeffrey A Bender, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 220 Burdette St, Saint Ignace, MI 49781 Phone: 906-643-8585 Fax: 906-643-0463 |
News Archive
Changes in vaginal pH as a result of common "pH triggers" make women more susceptible to infections such as bacterial vaginosis (BV). Understanding how the vaginal environment responds to pH fluctuation helps health professionals prevent and treat these conditions.
Neuroscientists have published findings which reveal that the motor region for the hand connects to the entire body.
Castle Biosciences Inc. announced that data from studies of its DecisionDx-Melanoma test are being presented today at the Summer Academy Meeting of the American Academy of Dermatology. The validation data confirm previous studies showing that the gene expression profile test is a strong independent predictor for classifying which Stage I or II non-metastatic cutaneous melanoma patients will likely recur.
New cases of diabetes continue to increase as does the health burden for those with diabetes. Law is a critical tool for health improvement, yet assessments reported in a new study published in the American Journal of Preventive Medicine indicate that federal, state, and local laws give only partial support to guidelines and evidence-based interventions relevant to diabetes prevention and control.
NeoRx Corporation today announced that it has acquired from AnorMED Inc. the worldwide exclusive rights, excluding Japan, to develop, manufacture and commercialize AMD473, a platinum-based anti-cancer agent. AMD473 has been administered to more than 500 cancer patients in phase I and phase II clinical trials, demonstrating anti-cancer activity in a wide range of tumors and a manageable safety profile. NeoRx expects to initiate clinical studies of AMD473 in one or more cancer indications in the second half of this year.
› Verified 4 days ago